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Mitochondria contribute to shape intraneuronal Ca2+ signals. Excessive Ca2+ taken up by
mitochondria could lead to cell death. Amyloid beta (Aβ) causes cytosolic Ca2+ overload, but
the effects of Aβ on mitochondrial Ca2+ levels in Alzheimer’s disease (AD) remain unclear.
Using a ratiometric Ca2+ indicator targeted to neuronal mitochondria and intravital multi-
photon microscopy, we find increased mitochondrial Ca2+ levels associated with plaque
deposition and neuronal death in a transgenic mouse model of cerebral β-amyloidosis.
Naturally secreted soluble Aβ applied onto the healthy brain increases Ca2+ concentration in
mitochondria, which is prevented by blockage of the mitochondrial calcium uniporter. RNA-
sequencing from post-mortem AD human brains shows downregulation in the expression of
mitochondrial influx Ca2+ transporter genes, but upregulation in the genes related to mito-
chondrial Ca2+ efflux pathways, suggesting a counteracting effect to avoid Ca2+ overload.
We propose lowering neuronal mitochondrial Ca2+ by inhibiting the mitochondrial Ca2+
uniporter as a novel potential therapeutic target against AD.
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A lzheimer’s disease (AD), the most common age-relatedneurodegenerative disorder, is characterized by depositionof extracellular senile plaques, neurofibrillary tangles and
neurodegeneration, which lead to cognitive impairment and
dementia. Despite the extensive efforts to understand its patho-
physiology, the exact mechanisms underlying AD remain
unknown. The most influential hypothesis for AD postulates that
abnormal accumulation of the amyloid β (Aβ) peptide is the
precipitating event that triggers a pathogenic cascade of adverse
events, and that Aβ oligomers (Aβo), rather than amyloid plaques
themselves, are the neurotoxic species of Aβ1 linked to tau
aggregation2. Aβ neurotoxicity has also been associated with
intraneuronal Ca2+ dyshomeostasis3. The calcium hypothesis of
AD4 posits that activation of the amyloidogenic pathway remo-
dels neuronal Ca2+ signaling, altering normal Ca2+ homeostasis
and the mechanisms responsible for learning and memory.
Previous work from our group and others has shown that Aβ
aggregates increase cytosolic Ca2+ levels in vivo both in a mouse
model of AD5,6, and after application of soluble Aβo to the brain
of naive wild-type (Wt) mice7,8. However, these investigations
assessed Ca2+ levels in the cytosol, and whether Aβ affects Ca2+
levels in mitochondria in vivo remains elusive.
Mitochondrial malfunction has been proposed as an early
event in AD and other aging-related neurodegenerative dis-
orders9. Studies on brains from AD patients and AD mouse
models have shown impaired mitochondrial function, manifested
as decreased bioenergetics and ATP synthesis10, morphological
abnormalities11, imbalance of mitochondrial dynamics12 and
redistribution of mitochondria13. Mitochondria participate in
intracellular Ca2+ signaling as modulators, buffers and sensors14.
After a cytosolic Ca2+ increase, mitochondria rapidly take up
Ca2+ to prevent Ca2+ overload into the cytosol. However,
excessive Ca2+ taken up into mitochondria, i.e., mitochondrial
Ca2+ overload, results in increased reactive oxidative species
(ROS) production, ATP synthesis inhibition, mitochondrial per-
meability transition pore (mPTP) opening, release of cytochrome
c, activation of caspases and apoptosis15. In vitro studies have
reported that Aβo induce mitochondrial Ca2+ uptake16,17, and
Ca2+ transfer from ER to mitochondria18 in cultured rat primary
neurons, but whether these findings apply in vivo remains
unknown. In the present study, we assess whether Aβ aggregates
alter mitochondrial Ca2+ levels in neurons in the mouse brain
in vivo. We find elevated Ca2+ levels in neuronal mitochondria in
transgenic mice, but only after plaque deposition, and preceding
neural death. This mitochondrial Ca2+ overload in vivo involves
toxic extracellular Aβ oligomers and requires the mitochondrial
Ca2+ uniporter. We propose reducing mitochondrial Ca2+
overload by blocking the mitochondrial Ca2+ uniporter as a novel
potential therapeutic target for AD.
Results
Functional AAV.hSyn.2mtYC3.6 targets neuronal mitochon-
dria. We have previously observed cytosolic Ca2+ overload5 and
mitochondrial membrane potential decrease11 in the APPswe/
PSEN1ΔE9 (APP/PS1) Tg mouse after amyloid plaque deposi-
tion. Here we hypothesized that Aβ aggregates could also increase
neuronal mitochondrial Ca2+ levels in vivo. To study free Ca2+
concentration in mitochondria ([Ca2+]mit) in neurons, we tar-
geted the expression of the ratiometric Ca2+ indicator Yellow
Cameleon 3.6 (YC3.6)19 to neuronal mitochondria (Fig. 1a).
YC3.6 allows visualization of subcellular Ca2+ concentration
based on Förster resonance energy transfer (FRET) imaging
between CFP and YFP, quantitatively measuring absolute Ca2+
concentrations. YC3.6 is one of the brightest reporters among the
YC versions, and exhibits a large dynamic range and excellent
signal-to-noise ratio19. Detailed characterization of hSyn.2m-
tYC3.6 expression was performed in vitro using neuroblastoma
Neuro2a cells (N2a) and mouse primary cortical neurons, and
ex vivo after immunofluorescence of sections from a Wt adult
mouse brain injected with AAV.hSyn.2mtYC3.6. The punctate
and perinuclear pattern expression of 2mtYC3.6 (Fig. 1b, c)
suggested its mitochondrial localization. Co-transfection of cells
with hSyn.2mtYC3.6 and mRuby-Mito-7 confirmed mitochon-
drial colocalization of 2mtYC3.6 (Fig. 1b). Co-labeling of AAV.
hSyn.2mtYC3.6 with HSP60 antibody (Heat shock protein 60,
localized to the mitochondrial matrix) in tissue sections corro-
borated the mitochondrial and neuronal-specific expression of
the 2mtYC3.6 in vivo (Fig. 1c and Supplementary Fig. 1).
We calibrated hsyn.2mtYC3.6 in N2a cells. Cells were
transfected with hSyn.2mtYC3.6, and 24 h later, cells were
permeabilized and exposed to solutions containing increasing
known [Ca2+] (Methods). An increase in the YFP/CFP fluores-
cence ratio of YC3.6 corresponds to an increase in [Ca2+]. Ratios
of YFP/CFP fluorescence intensities were plotted against [Ca2+]
and fitted with a sigmoidal curve (Fig. 1d). We observed nearly
4-fold increase in the ratio at high [Ca2+]mit (Rmin=0.606, Rmax=
2.6921), with an apparent Kd (Kd′) of 4.21 µM and a Hill
coefficient of 1.5720. Either the mitochondrial environment or the
fusion of two mitochondrial sequences shifted the affinity of
YC3.6 for Ca2+ to higher values, making it more suitable for Ca2+
measurements in mitochondria. This calibration was used
to obtain [Ca2+]mit in the subsequent experiments. To verify
that AAV.hSyn.2mtYC3.6 was functional in vivo, we applied
KCl topically onto the brain of C57BL/6J mice injected with
AAV.hSyn.2mtYC3.6 to induce neuronal depolarization, and
imaged the neuronal mitochondria with multiphoton microscopy.
Figure 1e and Supplementary Video 1 show an increase in the
YFP/CFP ratio, representing [Ca2+]mit (pseudocolored images and
Ca2+ recording), immediately after KCl application. Therefore,
AAV.hSyn.2mtYC3.6 specifically targets mitochondria in neurons,
can be expressed in vivo and provides a quantitative readout of
neuronal [Ca2+]mit.
We compared the kinetics of cytosolic Ca2+ versus mitochon-
drial Ca2+ in primary neurons upon KCl-induced depolarization.
We loaded cortical neurons with the cytosolic Ca2+ indicator
calbryte 590, and infected them with our mitochondrial reporter
hSyn.2mtYC3.6, to measure Ca2+ changes in the cytosol and
mitochondria simultaneously (Supplementary Fig. 2). Application
of KCl increased both cytosolic Ca2+ concentration ([Ca2+]cyt)
and [Ca2+]mit. However, mitochondria exhibit different kinetics,
which justified the need to address the mitochondrial Ca2+
impairment independent of cytosolic Ca2+ in the disease model.
Mitochondrial Ca2+ overload in vivo after Aβ plaque deposi-
tion. To address whether there are alterations in mitochondrial
Ca2+ contributing to a general Ca2+ dyshomeostasis in AD, we
examined [Ca2+]mit in the APP/PS1 Tg mouse model of cerebral
β-amyloidosis in vivo using multiphoton microscopy. Age-
matched Wt littermates were used as controls. 8-months-old
(mo-old) APP/PS1 Tg mice were intracortically injected with
AAV.hSyn.2mtYC3.6 targeting layers II/III, and 5 mm diameter
cranial windows were implanted over the somatosensory cortex.
Imaging was conducted 3 weeks later to allow for protein
expression. Methoxy X0-4 was injected intraperitoneally 24 h
before to label amyloid plaques21 (Fig. 2a). [Ca2+]mit was assessed
by acquiring volumes of different regions of the cortex and
determining the YFP/CFP ratio in the individual mitochondria.
Figure 2b shows in vivo multiphoton microscopy images of
mitochondria in neurons after transduction by AAV.hSyn.2m-
tYC3.6 in 9-mo-old Wt (top panel) and APP/PS1 Tg mice
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16074-2
2 NATURE COMMUNICATIONS |         (2020) 11:2146 | https://doi.org/10.1038/s41467-020-16074-2 | www.nature.com/naturecommunications
2 mitochondrial
targeting sequence ECFP XCaM M13 cp173Venus ITRITR hSyn promoter WPRE
hSyn.2mtYC3.6
































































































Fig. 1 hSyn.2mtYC3.6 targets neuronal mitochondria and is functional in vivo. a Diagram of construct AAV.hSyn.2mtYC3.6-WPRE. b Mitochondrial
counter labeling of 2mtYC3.6 verified proper targeting to mitochondria. N2a cells (top) and primary cortical neurons (bottom) were co-transfected with
hSyn.2mtYC3.6 (green) and mRuby-Mito-7 (red) and subjected to confocal microscopy imaging. Scale bar 10 µm. c Colocalization of HSP60 (red) and
hSyn.2mtYC3.6 (green) in cortex shown by immunohistochemistry (top). Scale bar 20 µm. Bottom graph shows intensity profile of the ROI across the cell
(inset, scale bar 10 µm). Green line represents the intensity of hSyn.2mtYC3.6 and red line represent the intensity of HSP60. d In vitro calibration of 2mtYC3.6.
Primary cortical neurons and N2a cells were exposed to varying [Ca2+] solutions, and relative changes in YFP/CFP ratio vs. [Ca2+] are indicated. Left, images
are pseudocolored according to the color bar. Scale bar 10 µm. Right, titration curve of 2mtYC3.6 in N2a cells, two independent experiments, number of cells:
0 µM, n= 233; 0.2 µM, n= 339; 0.575 µM, n= 436; 1 µM, n= 332; 2 µM, n= 321; 5.7 µM, n= 356; 10 µM, n= 295; 20 µM, n= 317; 53 µM, n= 372; 100 µM,
n= 372; 200 µM, n= 292; 500 µM, n= 209; 1000 µM, n= 274. e Validation of AAV.hSyn.2mtYC3.6 in vivo. Left, multiphoton microscopy imaging of the
expression of AAV.hSyn.2mtYC3.6 in the cortex of a C57BL/6 J mouse. Scale bar 20 µm. Middle, pseudocolored images of the mitochondria expressing AAV.
hSyn.2mtYC3.6 in basal conditions and after KCl application. Right, recording of the application of KCl to the brain. Gray traces represent single-cell responses
and red trace represents averaged (mean ± SEM) [Ca2+]mit responses to 300mM KCl. Representative of three mice.
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(bottom panel). On average, 9-mo-old APP/PS1 Tg mice exhib-
ited higher YFP/CFP ratios than 9-mo-old Wt mice (Fig. 2c).We
also evaluated mitochondrial Ca2+ overload using frequency
distribution histograms (Fig. 2d). A general shift towards higher
YFP/CFP ratios (higher [Ca2+]mit) was observed for APP/PS1 Tg
mice. Ca2+ overload was defined as YFP/CFP ratio greater than
two standard deviations (SD) above the mean YFP/CFP ratio
obtained for all the mitochondria in all Wt mice5,7,22 (dashed
line, YFP/CFP ratio >0.99, ~1637 nM [Ca2+]mit). Twice as many
mitochondria from APP/PS1 Tg mice showed Ca2+ overload
compared to Wt mice (Fig. 2e). [Ca2+]mit was also higher in the
APP/PS1 Tg mice in both somas and neurites (Fig. 2f).
Next, we assessed whether the presence of Aβ plaques was
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preceded plaque formation. APP/PS1 Tg mice start developing
amyloid plaques at 4–5 mo-old23. No differences in YFP/CFP
ratio or Ca2+ overload were detected between Wt and APP/PS1
mice at 2.5–3-mo-old (before plaque deposition), in either somas
or neurites (Supplementary Fig. 3). Histograms in Supplementary
Fig. 3 show that at this age there is no shift toward higher
YFP/CFP ratios in APP/PS1 Tg mice relative to Wt mice at this
early age. This is consistent with previous studies reporting no
changes in [Ca2+]cyt and neuronal function prior to plaque
deposition5,24,25, supporting the idea that mitochondrial Ca2+
overload in neurons follows, rather than precedes, amyloid plaque
deposition.
Mitochondrial Ca2+ is independent from the distance to pla-
ques. Individual Aβ plaques were previously reported to increase
the likelihood of Ca2+ overload in the cytosol of neurites and cell
bodies within a range of ~20–30 µm from the plaque edge5,6 in
APP/PS1 Tg mice. To test whether Aβ plaques have local effects
on the [Ca2+]mit in these mice, we measured mitochondrial Ca2+
overload relative to the distance between each mitochondrion and
the edge of the nearest amyloid plaque. No significant differences
were found in the average mitochondrial Ca2+ overload as a
function of distance to plaques in either cell bodies or neurites
(Fig. 3a, b), suggesting that soluble Aβo species, rather than Aβ
plaques per se, are likely responsible for the increase of neuronal
[Ca2+]mit. Indeed, it has been shown that the concentration
of soluble Aβo in the brain of this mouse model increases
with age23,26,27, which could explain the observed age-related
[Ca2+]mit increase.
Soluble Aβ increases mitochondrial Ca2+ in Wt mice neurons.
We have previously shown that acute exposure of the brain of
naive (Wt) living mice to soluble Aβo leads to disruption of
cytosolic Ca2+ homeostasis in neurons7. To test the hypothesis
Fig. 2 Mitochondrial Ca2+ overload after Aβ plaque deposition. a Experimental procedure to determine [Ca2+]mit in neurons in APP/PS1 Tg mice. 8-mo-
old mice were injected with AAV.hSyn.2mtYC3.6 and a cranial window was implanted. Three weeks later, [Ca2+]mit was assessed by multiphoton
microscopy. b In vivo multiphoton microscopy images of mitochondria expressing AAV.hSyn.2mtYC3.6 in Wt (top) and APP/PS1 Tg mice (bottom). Field
of view shows AAV.hSyn.2mtYC3.6 in mitochondria (green), and blood vessels labeled with Dextran 70,000MW (red). FRET-based Ca2+ imaging shows
pseudocolored images of the field of view (scale bar 20 µm) and the inset from the white box (scale bar 5 µm). c Nine-mo-old APP/PS1 Tg mice exhibited
increased ration YFP/CFP when compared to 9-mo-old Wt mice. Scatter dot plot representing the ratio YFP/CFP of every volume acquired. Error bars
represent mean ± SEM. **p= 0.0015 (0.67 ± 0.011 (~472 nM [Ca2+]mit), n= 100 z-stacks from 11 Wt mice, and 0.73 ± 0.014 (~731 nM [Ca2+]mit), n= 70
z-stacks from 7 APP/PS1 Tg mice). d Histogram of [Ca2+]mit frequency distribution (indicated by YFP/CFP ratio). The black dotted line corresponds to
2 SD above the mean [Ca2+]mit in Wt mice (YFP/CFP ratio >0.99, ~1637 nM). Ratios above this line were classified as mitochondrial Ca2+ overload.
e Comparison of the percentage of Ca2+-overloaded mitochondria in 9-mo-old Wt and APP/PS1 Tg mice. APP/PS1 Tg mice exhibited significantly higher
percentage of mitochondria with elevated Ca2+. Scatter dot plot represents the percentage of Ca2+-overloaded mitochondria of every volume acquired.
Error bars represent mean ± SEM. ***p= 0.001 (5.4 ± 0.79% from n= 70 z-stacks from 7 APP/PS1 Tg mice vs. 2.6 ± 0.51% from n= 100 z-stacks from 11
Wt mice). f Comparison of [Ca2+]mit (YFP/CFP ratio) in the different compartments (somas and neurites) in 9-mo-old Wt and APP/PS1 Tg mice. APP/PS1
Tg mice exhibited significantly higher Ca2+ levels in mitochondria both in somas and neurites. Error bars represent mean ± SEM. ****p < 0.0001 (Somas:
0.77 ± 0.01, n= 21 z-stacks from 3 Wt mice, and 0.82 ± 0.01, n= 18 z-stacks from 3 APP/PS1 Tg mice. Neurites: 0.67 ± 0.01, n= 21 z-stacks from 3 Wt
mice, and 0.76 ± 0.01, n= 18 z-stacks from 3 APP/PS1 Tg mice). a Created using modified Servier Medical Art templates, which are licensed under a
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Fig. 3 Mitochondrial Ca2+ overload is independent of the distance to plaques. a In vivo multiphoton microscopy pseudocolored images of AAV.
hSyn.2mtYC3.6 expressing mitochondria in 9-mo-old APP/PS1 Tg mice. Elevated [Ca2+]mit was observed in mitochondria at <30 µm distance (left), but
also at >30 µm distance (right). Arrow heads show mitochondria with Ca2+ overload in neuronal soma (top, scale bar 50 µm) and neurites (bottom, scale
bar 10 µm). b Within 100 µm distance from the edge of a plaque, the probability of finding mitochondrial Ca2+ overload did not change. n= 31 plaques
analyzed from 5 Tg mice (mean ± SEM, n.s. non-significant). The percentage of mitochondria showing Ca2+ overload in Wt mice is shown as reference
(blue dotted line).
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that soluble Aβ is responsible for the [Ca2+]mit increase, we
topically applied naturally secreted soluble Aβo onto the brain of
Wt mice expressing AAV.hSyn.2mtYC3.6, and assessed [Ca2+]mit
with multiphoton microscopy. Aβo-enriched medium was
obtained from primary cortical neurons isolated from Tg2576
embryos (APP Swedish mutation) (Tg-conditioned media,
TgCM), which mainly contains low molecular weight oligomers
(dimers to tetramers)7,28. CM from Wt-littermate neurons
(WtCM) and Aβ-immunodepleted TgCM were used as controls.
The three media were subjected to an Aβ40 sandwich ELISA. Aβ40
concentration in the media was 0.3, 5 and 0.7 nM for WtCM,
TgCM and Aβ-immunodepleted TgCM, respectively. Aβo con-
centration in TgCM represents around 10% of the total amount
of Aβ407.
To assess the effects of CM on [Ca2+]mit in the healthy brain, a
cranial window was implanted over the somatosensory cortex of
4- to 5-mo-old C57BL/6J mice injected with AAV.hSyn.2mtYC3.6,
the mouse was imaged at baseline, the window was reopened to
apply either WtCM, TgCM or Aβ-depleted TgCM onto the brain
for 1 h, and finally, the mouse was reimaged in the same volumes
imaged at baseline (Fig. 4a, b). Mitochondrial Ca2+ overload was
defined as the YFP/CFP ratio greater than 2SD above the mean
YFP/CFP ratio of all the mitochondria imaged under basal
conditions (YFP/CFP ratio >0.98, (~1604 nM [Ca2+]mit)).
Application of TgCM significantly increased [Ca2+]mit, causing a
shift towards higher YFP/CFP ratios (higher [Ca2+]mit) in the
[Ca2+]mit histogram (Fig. 4c, middle). The proportion of
mitochondria with Ca2+ overload after application of TgCM
was significantly different than in basal conditions (Fig. 4d,
middle). By contrast, topical application of WtCM did not
increase [Ca2+]mit (Fig. 4c, left). To further validate that Aβo are
responsible for the mitochondrial Ca2+ overload, we immunode-
pleted human Aβ from the TgCM with an anti-β-Amyloid
antibody (β-amyloid 1–16, 6E10). Per ELISA measurements,
immunodepletion of Aβ effectively removed about 85% of Aβ
present in TgCM, from 5 to 0.7 nM (final Aβ40 concentration).
Application of Aβ-immunodepleted TgCM did not increase
[Ca2+]mit (Fig. 4c, right) compared to basal conditions. Compar-
ing the averaged YFP/CFP ratios in each volume (from all
mitochondria in each z-stack) acquired before and after applica-
tion of CM (Fig. 4e), the majority of z-stacks analyzed after the
application of TgCM were increased by 5% or more (dark lines),
whereas only a few z-stacks showed a ≥5% increase for WtCM and
Aβ-immunodepleted TgCM. Using these ratios, we calculated the
relative change in YFP/CFP ratio (ΔR/R0) for each z-stack.
Application of TgCM induced a relative change in the YFP/CFP
ratio significantly higher than WtCM or Aβ-immunodepleted
TgCM (Fig. 4f). This effect was more prominent in neurites
(Fig. 4g). These relatively small, but significant differences, suggest
that a small fraction of neuronal mitochondria are affected by
TgCM, similar to our observation in plaque-bearing APP/PS1 Tg
mice, and implicate of soluble Aβo in mitochondrial Ca2+
overload in neurons in vivo.
MCU is required for Aβo-driven mitochondrial Ca2+ uptake.
The main Ca2+ uptake pathway in mitochondria is the mito-
chondrial Ca2+ uniporter (MCU) complex, which includes the
MCU pore, located in the inner mitochondrial membrane29,30,
and the combination of two regulatory subunits MiCU1 and
MiCU2 (mitochondrial calcium uptake 1 and 2 proteins), which
regulate the MCU response to extra-mitochondrial Ca2+ 31,32.
Other proteins involved in the complex include the essential
MCU regulator (EMRE)33, MCUb34, or MiCU335. Mitochondrial
Ca2+ efflux depends mainly on the electrogenic Na+-dependent
Ca2+ release exchanger (NCLX)36. Given the increased number
of mitochondria with Ca2+ overload in APP/PS1 Tg mice after
amyloid plaque deposition, we performed Western blots for
MCU, MiCU1, MiCU2, and NCLX in mitochondrial-enriched
fractions of the brain of 10-mo-old Wt and APP/PS1 Tg mice to
test whether Aβ affects the expression levels of these proteins. No
significant differences were detected between genotypes in any of
these mitochondrial proteins (Supplementary Fig. 4).
To test whether Aβo induce mitochondrial Ca2+ increase in
neurons via the MCU complex, we blocked the pore with the
specific cell-permeable MCU inhibitor Ruthenium 360 (Ru360)37.
As in Fig. 4a, C57BL/6J Wt mice expressing hSyn.2mtYC3.6 were
subjected to a craniotomy, and [Ca2+]mit was assessed in basal
conditions. The window was then reopened and the underlying
brain was pre-treated with Ru360 (100 µM) for 15 min. TgCM
mixed with Ru360 was next applied onto the brain for 1 h, and
the mouse was reimaged in the same areas. TgCM increased
neuronal [Ca2+]mit (arrow heads) as expected, but application of
TgCM mixed with Ru360 did not (Fig. 5a). Pre-treatment with
Ru360 did not shift the distribution of YFP/CFP ratios when
compared to TgCM alone (Fig. 5b), and the proportion of
mitochondria with Ca2+ overload, (YFP/CFP ratio >1.01 (~1704
nM [Ca2+]mit)), was not significantly different (Fig. 5c). Topical
application of Ru360 alone did not have an effect on [Ca2+]mit.
Comparing the average YFP/CFP ratio in each volume acquired
before and after application of TgCM with Ru360, only a few
volumes increased 5% or more (dark lines), whereas for the
majority the increase was ≤5% (light lines) (Fig. 5d). Average of
the relative change in YFP/CFP ratio (ΔR/R0) for each volume
(Fig. 5e) showed that application of TgCM without Ru360
induced a change in YFP/CFP ratio significantly different from
the application of TgCM with Ru360. Importantly, Ru360
application did not inhibit the rise of Ca2+ in the cytosol
induced by TgCM (as tested in C57Bl/6J mice injected with CBA.
YC3.65) (Supplementary Fig. 5), suggesting that Ru360 did not
render neurons insensitive to Aβo or blocked channels/influx
pathways in the plasma membrane. These data suggest that MCU
is required for the Aβ-driven mitochondrial Ca2+ increase in
neurons in the brain in vivo.
Mitochondrial Ca2+ precedes neuronal death. We next asked
whether the excessive Ca2+ could have a detrimental effect in
Ca2+ overloaded mitochondria and, eventually, also in the neu-
rons containing these mitochondria. We examined the time
course of Aβo-driven neuronal mitochondrial Ca2+ overload in
the C57BL/6 J Wt mouse brain, and specifically asked whether
this was permanent or reversible and, if the latter, how long after
Aβo application. At 8 h post-application of TgCM, neuronal
[Ca2+]mit had already returned to basal levels (Fig. 6d–e). As
expected, WtCM had no effect on [Ca2+]mit (Fig. 6a–c). Despite
the relatively transient mitochondrial Ca2+ overload associated to
acute topical application of Aβo, we noted altered mitochondria
shape and size at 8 h only with TgCM (but not with WtCM)
compared to basal conditions (Fig. 6a, d, insets; Supplementary
Figs. 6 and 7), in agreement with previous reports showing
mitochondrial morphological abnormalities in the human AD
brain and AD Tg mice11,38.
Because mitochondrial Ca2+ overload can lead to apoptosis39,
we examined the viability of neurons with chronic (rather than
transient) mitochondrial Ca2+ overload using longitudinal
multiphoton microscopy serial imaging over a 24–48 h period
in 9-mo-old APP/PS1 Tg mice. First, we evaluated whether the
static mitochondrial Ca2+ levels were stable longitudinally. We
observed that over 3 imaging sessions (48 h), the absolute
mitochondrial Ca2+ levels were constant in the same cell, for
both low and intermediate Ca2+ levels (Fig. 7a). Surprisingly, a
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small fraction of neurons with extremely high [Ca2+]mit in their
somas at the first imaging session (on average, YFP/CFP ratio
≥1.4, (~3093 nM [Ca2+]mit)) were lost within 24 h (Fig. 7b, c).
None of the neurons exhibiting YFP/CFP ratio ≤1.4 disappeared
in the second imaging session. We concomitantly injected
Hoechst 33342 with hSyn.2mtYC3.6 to observe the nucleus and
[Ca2+]mit simultaneously. We observed that the nucleus from
healthy neurons was spherical and chromatin was evenly
distributed. Conversely, in neurons with high [Ca2+]mit at
baseline, the nucleus became condensed (likely undergoing
apoptosis), and the soma lost its of YFP/CFP fluorescence
(Fig. 7c). Despite being an occasional event in this model40, this
observation suggests a close correlation between high [Ca2+]mit
and neuronal cell death.
Field of view
AAV.hSyn.2mtYC3.6
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To further understand the effects of increased mitochondrial
Ca2+ concentration and the connection to neuronal death, we
performed some mechanistic studies in vitro using mouse
primary cortical neurons exposed to TgCM. First, we determined
that TgCM increased [Ca2+]mit in primary neurons (infected
with hSyn.2mtYC3.6) (Supplementary Fig. 8A) within 1 h,
corroborating the in vivo data. In addition, TgCM decreased
the mitochondrial membrane potential (ΔΨm) (measured with
TMRE) (Supplementary Fig. 8D), activated the mPTP (evaluated
by calcein/cobalt fluorescence) (Supplementary Fig. 8C), and
activated caspases 3/7 (detected with CellEvent Caspase 3/7) in
primary neurons (Supplementary Fig. 8E). These effects took
place in the same time window as the increase of [Ca2+]mit.
WtCM did not drive any of these effects on mitochondria.
Blocking of the mPTP with cyclosporine A (CsA)41, as verified by
calcein/cobalt fluorescence, prevented the decrease of ΔΨm, but
did not inhibit the increase of [Ca2+]mit elicited by TgCM. These
results suggest that the reduction of ΔΨm is driven by the
increase in mitochondrial Ca2+ after TgCM application. Blocking
mPTP with CsA showed a trend towards decreasing the number
of neurons with caspase 3/7 activation (Supplementary Fig. 8).
Mitochondrial Ca2+ dyshomeostasis in the human AD brain.
Finally, we sought to test whether mitochondrial Ca2+ dysho-
meostasis is relevant to the human AD brain. Expression of
mitochondrial genes encoding proteins involved in Ca2+ trans-
port was assessed using gene differential expression data publicly
available at the Accelerating Medicines Partnership-Alzheimer’s
Disease (AMP-AD) Knowledge Portal42. We evaluated 25 pub-
licly available microarray and RNA-Sequencing datasets from the
Mount Sinai Brain Bank (MSBB)43 and the Religious Orders
Study and Memory and Aging Project (ROSMAP)44 cohorts, and
compared the transcript levels of mitochondrial Ca2+-related
genes between subjects with AD (Braak stages V–VI) and control
individuals (Braak stages 0–I–II), specifically MCU, MCUB,
MCUR1, MICU1, MICU2, MICU3 and SMDT1 for mitochondrial
Ca2+ influx, and SLC8B1 (encoding NCLX) for mitochondrial
Ca2+ efflux. Surprisingly, the mitochondrial Ca2+ uniporter
(Mcu) and its regulatory subunits (Micu1, Micu2, Micu3 and
Smdt1) are significantly downregulated (p < 0.05 and FDR < 25%)
in AD compared to control subjects after adjusting for neuronal
loss with the pan-neuronal marker Map2 (Supplementary Fig. 9,
Supplementary Table 1). Interestingly, the Ca2+ efflux gene
Slc8b1 is significantly upregulated. Mcur1 is also downregulated
in the frontal pole and the superior temporal gyrus but fell just
below the FDR threshold. No change was observed in Mcub.
Analyses by CERAD scores (frequent versus absent neuritic
amyloid plaques)45 produced similar results (Supplementary
Table 2). All genes for mitochondrial Ca2+ influx were down-
regulated (FDR < 20%), whereas Slc8b1 was upregulated. Mcur1
was also upregulated in this case. These results suggest that the
expression of most of human genes involved in mitochondrial
Ca2+ transport is altered in AD patients, denoting a counter-
acting effect to avoid mitochondrial Ca2+ overload.
The present results suggest that Aβ aggregates (likely soluble
Aβo) lead to mitochondrial Ca2+ overload in AD. Aβ-induced
mitochondrial Ca2+ uptake requires MCU, as blocking MCU
with the specific inhibitor Ru360 prevents the Ca2+ overload.
In addition, excessive Ca2+ taken up by mitochondria leads to
opening of the mitochondrial permeability transition pore
(mPTP), caspase activation and, eventually, neuronal cell death
(Fig. 8).
Discussion
Proposed mechanisms of neurotoxicity in AD include the dis-
ruption of Ca2+ homeostasis and mitochondrial dysfunction,
which contribute to synaptic and neuronal damage46. An exten-
sive array of in vitro and in vivo studies has shown that Aβ
aggregates alter cytosolic Ca2+ homeostasis. However, prior stu-
dies linking Aβ with mitochondrial Ca2+ overload16,17 have used
cultured cells and high concentrations of synthetic Aβo, and
whether there is mitochondrial Ca2+ overload elicited by Aβ
aggregates in vivo remained an open question to date. In the
present study, we provide evidence of in vivo mitochondrial Ca2+
overload in a Tg mouse model of cerebral β-amyloidosis, and
after topical application of natural soluble Aβo at concentrations
similar to those found in the AD brain.
We found mitochondrial Ca2+ overload in the APP/PS1 Tg
mouse, a model that recapitulates an accelerated deposition of
amyloid plaques. This overload was observed in the Tg mice once
the Aβ plaques were present. The mitochondrial Ca2+ increase
was of a higher magnitude than the cytosolic Ca2+ levels observed
in the same mouse model5. Whereas Ca2+ levels in the neuronal
cytosol upon exposure to Aβo were in the nM range7, mito-
chondrial Ca2+ levels were in the µM range. This was not sur-
prising as mitochondria take up large amounts of Ca2+ during
physiological Ca2+ elevations. Indeed, effective mitochondria
Ca2+ buffering capacity was reported ~0.2–2 µM in isolated brain
Fig. 4 Soluble Aβ increases mitochondrial Ca2+ concentration in neurons in vivo. a Experimental procedure: 4-mo-old C57BL/6J mice were injected with
AAV.hSyn.2mtYC3.6. A cranial window was implanted the day of the experiment (3 weeks later). [Ca2+]mit was assessed in basal conditions. Then, the
window was reopened and either WtCM, TgCM or Aβ-immunodepleted TgCM was applied for 1 h. Finally, the mouse was reimaged in the exact same
regions as for basal conditions. b Representative pictures of the effects of CM in the healthy living mouse brain. Arrow heads show mitochondria with high
[Ca2+]. Scale bar 20 and 5 µm for the inset. c Histograms of [Ca2+]mit frequency distribution (YFP/CFP ratio) for the three conditions before (basal) and
after application of CM. The black dotted line corresponds to 2SD above the mean [Ca2+]mit measured for all mice in baseline. Ratios above this line were
classified as mitochondrial Ca2+ overload. d Scatter dot plot represents the percentage of mitochondria showing Ca2+ overload before and after
application of CM for every volume acquired. Error bars represent mean ± SEM (WtCM: before 2.45 ± 0.43% vs. after 2.92 ± 0.49%; non-significant, n=
32 z-stacks from 5 mice. TgCM: before 2.89 ± 0.47% vs. after 7.53 ± 1.09%; ****p < 0.0001, n= 48 z-stacks from 7 mice. Aβ-depleted TgCM: before 2.43
± 0.13% vs. after 2.66 ± 0.20%; non-significant, n= 38 from z-stacks 5 mice). The percentage of Ca2+ overload before (basal) and after CM application is
also noted on the graphs. e Averaged YFP/CFP ratios before and after treatment for each z-stack acquired. The dark traces account for the z-stacks
showing an increase ≥5% in YFP/CFP ratio after topical application of CM. f Scatter dot plot represents the relative change in ratio for each condition. Error
bars represent mean ± SEM (WtCM: 0.20 ± 1.09%, n= 32 z-stacks; TgCM: 7.59 ± 0.92%, 48 z-stacks; depleted TgCM 1.20 ± 1.05%, 38 z-stacks from 5, 7
and 5 mice, respectively, ****p < 0.0001). g Relative increase of [Ca2+]mit (ΔR/R0) in the different compartments (somas and neurites) after WtCM or
TgCM application. Error bars represent mean ± SEM. **p < 0.005 (Somas: 0.79 ± 0.91, n= 8 z-stacks from 3 WtCM application mice, and 3.10 ± 0.82, n=
10 z-stacks from 3 TgCM application mice. Neurites: −0.02 ± 1.44, n= 8 z-stacks from 3 WtCM application mice, and 10.15 ± 1.05, n= 10 z-stacks from 3
TgCM application mice). a Created using modified Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported
License (https://creativecommons.org/licenses/by/3.0/).
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Fig. 5 MCU is required for the Aβ-induced mitochondrial Ca2+ increase in vivo. a Representative pictures of the effects of the MCU complex blocker
Ru360 on the increase of [Ca2+]mit induced by TgCM. Arrow heads show mitochondria with high [Ca2+]. Scale bar 20 and 5 µm for the inset. b Graphs
show histogram of [Ca2+]mit frequency distribution (expressed as YFP/CFP ratio) before and after topical application of TgCM in presence of Ru360 and
of Ru360 alone. The percentage of Ca2+ overload before (basal) and after TgCM application in presence of Ru360 is noted. c Scatter dot plot represents
the percentage of mitochondria showing Ca2+ overload before and after application of CM for every volume acquired. Error bars represent mean ± SEM
(Ru360 + TgCM: before 2.37 ± 0.47% vs. after 1.89 ± 0.27%, non-significant, n= 28 z-stacks from 4 mice. Ru360: before 2.82 ± 0.86% vs. after 2.41 ±
0.78%, non-significant, n= 18 z-stacks from 3 mice). d Averaged YFP/CFP ratios before and after treatment for each z-stack acquired. The dark traces
account for the z-stacks that showed an increase ≥5% in YFP/CFP ratio after topical application of the treatment. e Scatter dot plot represent the relative
change in YFP/CFP ratio for each condition. Bars represent mean ± SEM (7.60 ± 0.81%, 48 z-stacks TgCM; −0.27 ± 1.05%, 28 z-stacks Ru360+TgCM;
−0.92 ± 1.25%, 18 z-stacks Ru360 from 7, 4 and 3 mice, respectively, ****p < 0.0001).
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Fig. 6 Soluble Aβ-driven mitochondrial Ca2+ increase recovers after 8 hours post-application. a Time-lapse images showing mitochondrial [Ca2+]
increase induced by WtCM, in basal conditions, 1 and 8 h after topical application. Scale bar 20 µm. b Histogram of [Ca2+]mit frequency distribution
(YFP/CFP ratio) before and 1 or 8 h after application of WtCM. The black dotted line corresponds to 2SD above the mean [Ca2+]mit measured for all
mitochondria before treatment. Ratios above this line were classified as mitochondrial Ca2+ overload. c Scatter dot plot represents the percentage of
mitochondria with Ca2+ overload at each time point in every volume acquired. Bars errors represent mean ± SEM (Basal 2.5 ± 0.54%, 1 h 2.7 ± 0.54%; 8 h
3.3 ± 0.54%; non-significant, n= 22 z-stacks from 3 mice). d Time-lapse images showing mitochondrial [Ca2+] increase induced by TgCM, in basal
conditions, 1 and 8 h after application. Scale bar 20 µm. e Histogram of [Ca2+]mit frequency distribution (YFP/CFP ratio) before and 1 or 8 h after
application of TgCM. Note that [Ca2+]mit distribution is shifted to higher YFP/CFP ratios at 1 h post- TgCM application, but recovers at 8 h post-TgCM
application. f Scatter dot plot represents the percentage of mitochondria with Ca2+ overload at each time point in every volume acquired. Error bars
represent mean ± SEM (Basal 3.2 ± 0.60%, 1 h 6.3 ± 1.22%; 8 h 3.7 ± 0.70%; *p < 0.05 vs. basal, n= 25 z-stacks from 5 mice).
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Fig. 7 Mitochondrial Ca2+ overload precedes neuronal death in the APP/PS1 Tg mice. a Time-lapse images showing that resting mitochondrial Ca2+
levels in neurons are steady over time in the 9-mo-old APP/PS1 Tg mouse. The same field of view was imaged at 3 different time points (3 consecutive
days). AAV.hSyn.2mtYC3.6 (neurons, green) and Dextran Texas Red (vessels) are shown in the top row and pseudocolor images in the bottom row. Insets
show somas of the same neuron during the time lapse. Scale bar 25 µm. b Time-lapse images showing mitochondrial Ca2+ overload preceding neuronal cell
death in a 9-mo-old APP/PS1 Tg mouse. Arrow heads show mitochondrial Ca2+ overload in the soma of a neuron, which disappeared 24 h later. Scale bar
20 µm. Scatter dot plot represents YFP/CFP ratio of single neurons present at baseline imaging session that remained or disappeared at 24 h follow-up
imaging session as a function of their baseline [Ca2+]mit. Neurons with a YFP/CFP ratio >1.4 disappeared within 24 h (mean ± SEM, n= 27 and 14 neurons
from 4 APP/PS1 mice, ****p < 0.0001, Student t-test). c Images show time-lapse recordings of nuclei and mitochondrial Ca2+ levels preceding neuronal cell
death in a 9-mo-old APP/PS1 Tg mouse. The same field of view was imaged at 2 different time points (2 consecutive days). AAV.hSyn.2mtYC3.6 (neurons,
green) and Dextran Texas Red (vessels) are shown in the top row, and pseudocolor images are shown in the middle (scale bar 20 µm) and bottom (scale
bar 5 µm) rows. 800 nm inset shows AVV (mitochondria, green) and Hoescht (nuclei, blue) acquired at 800 nm. It was observed that remaining cells (low
mitochondrial Ca2+) maintained a healthy nucleus (Hoechst), whereas disappearing cells (high mitochondrial Ca2+) presented a condensed nucleus.
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mitochondria47 and in neuronal mitochondria in situ48. In vivo,
we found that mitochondrial Ca2+ overload only occurs at levels
higher than ~1.6–1.7 µM, comparable to the reported buffering
capacity in vitro.
Mitochondrial dysfunction has been suggested as an early event
in AD, before plaque deposition9. However, several studies have
reported no change in resting cytosolic Ca2+ levels or neuronal
dysfunction before amyloid plaque deposition in AD mouse
models5,24,25. In agreement with these studies, there was no
appreciable mitochondrial Ca2+ overload in young mice before
plaque deposition (2.5–3-mo-old), suggesting that Aβ deposition is
necessary to trigger mitochondrial Ca2+ overload in neurons in
AD. Further longitudinal studies will be necessary to clarify whe-
ther mitochondrial Ca2+ elevation occurs concomitantly with
plaque formation. Surprisingly, no association was found between
mitochondrial Ca2+ overload and distance to amyloid plaques, in
contrast to cytosolic Ca2+ overload, wherein there was a higher
likelihood of detecting Ca2+ overload in the immediate vicinity
of individual plaques5. This suggests that diffusible soluble Aβ
oligomeric species rather than plaques are likely responsible for
the increase of [Ca2+]mit in the neurons of the APP/PS1 mouse,
or that mitochondria are less vulnerable than cytosol to the
pathophysiological insult mediated by Aβo. The intrinsic proper-
ties of mitochondria with regards to Ca2+ kinetics, and as dynamic
entities that undergo axonal transport, fusion/fission, and mito-
phagy when damaged, could also explain this difference.
To confirm that mitochondrial Ca2+ overload is triggered by
soluble Aβo, we directly applied naturally secreted Aβo (TgCM)
to the naive living mouse brain. Application of TgCM to the
cortical surface of the mouse brain increased [Ca2+]mit in neu-
rons within 1 h, whereas WtCM or Aβ-immunodepleted TgCM
did not. This result supports our previous findings in the APP/
PS1 model, and confirms a direct effect of Aβ aggregates altering
Ca2+ homeostasis in neurons. The reversibility of TgCM-induced
mitochondrial Ca2+ overload supports a normal extrusion via
mitochondrial Ca2+ exchangers, and/or clearance of the Aβo
from the brain parenchyma.
Mitochondria have been reported as a direct site of Aβ accu-
mulation in neurons in both human AD brains and AD Tg mouse
models49. However, the mechanism(s) by which Aβ evokes mito-
chondrial Ca2+ uptake in vivo has not been elucidated. Proposed
mechanisms include formation of Ca2+-permeable pores in the
plasma membrane and also in the membranes of intracellular
organelles50, or formation of a non-specific ion channel in the
plasma and mitochondrial membranes51. On the other hand, Ca2+
uptake into the mitochondrial matrix is mediated by the highly
conserved MCU complex29,30, which is selectively blocked by
Ru360. Our results show that pre-treatment with Ru360 abolishes
TgCM-induced mitochondrial Ca2+ uptake, providing evidence
that the MCU complex is required for the Aβ-driven mitochon-
drial Ca2+ increase in neurons in the brain in vivo, and arguing
against the formation of Ca2+-permeable pores or non-specific ion
channel in the mitochondrial membrane. However, assessment of
protein expression of the mitochondrial-enriched fraction extrac-
ted from Wt and APP/PS1 Tg mouse brains did not show any
significant differences between groups. Western blot might not be
sensitive enough to detect changes in protein levels that affect the
small subset of Ca2+-overloaded mitochondria seen in vivo.
Alternatively, Aβmay alter the levels of a component of the pore or
the NCLX exchanger not examined in this model due to lack of
adequate antibodies, or may impact their activity rather than
expression. Along these lines, recent work by Jadiya et al.52 has
observed a decrease in the expression of NCLX in mitochondria in
human AD brains and in mouse models of AD, linked to impaired
Ca2+ efflux from mitochondria, which could be responsible for the
disease progression.
To examine the relevance of mitochondrial Ca2+ dyshomeos-
tasis in the human AD brain, we took advantage of publicly
available microarray and RNA-Seq datasets, and compared the
expression levels of Ca2+-related mitochondrial genes in AD
patients (Braak stages V–VI) and control subjects (Braak stages
0–I–II). Most of the genes involved in Ca2+ influx into mito-
chondria were significantly downregulated in AD, whereas, the
only Ca2+ efflux gene was significantly upregulated. These results
most certainly point towards a compensatory effect in AD to
handle the mitochondrial Ca2+ overload, and confirm the exis-
tence of a mitochondrial Ca2+ dyshomeostasis in the human
AD brain.
Optimal mitochondrial activity is crucial to maintain neuronal
function and health. Mitochondria buffer Ca2+, and in turn, Ca2+
modulates mitochondrial activity. Excessive Ca2+ accumulation
into mitochondria leads to mitochondrial function impairment53,
which could lead to decreased ΔΨm11 and increased ROS pro-
duction40. Eventually, cytochrome c release and cell death via
apoptosis will take place39. Remarkably, when APP/PS1 Tg mice
were imaged longitudinally, the small fraction of neurons con-
taining mitochondria with elevated [Ca2+] in their cell bodies were


















Fig. 8 Schematic representing the effects of Aβ aggregates on
mitochondrial Ca2+ homeostasis. Under physiological conditions (normal),
mitochondria take up Ca2+ from the cytosol, via mitochondrial Ca2+
uniporter (MCU) complex, for activation of mitochondrial metabolism, TCA
cycle and OXPHOS, leading to ATP production. However, under pathological
conditions (AD), Aβ aggregates (likely soluble Aβo) increase cytosolic Ca2+,
thus leading to mitochondrial Ca2+ overload. Aβ-induced mitochondrial Ca2+
uptake is mediated via MCU, as blocking MCU with the specific inhibitor
Ru360 prevents it. Excessive Ca2+ taken up by mitochondria could lead to
opening of the mitochondrial permeability transition pore (mPTP), caspase
activation and, eventually, neuronal cell death. This figure was created using
modified Servier Medical Art templates, which are licensed under a Creative
Commons Attribution 3.0 Unported License (https://creativecommons.org/
licenses/by/3.0/).
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whereas neurons with physiological [Ca2+]mit and a healthy
spherical nucleus remained. Surprisingly, whereas the cells with
high [Ca2+]mit in the soma were likely to die, sporadic increases of
mitochondrial Ca2+ within the neurites were not as lethal. This
feature suggests that within the soma, high [Ca2+]mit represents an
“all or none”-phenomena, and not an isolated event in individual
mitochondria. The results obtained here in vivo are supported
by previous studies in vitro showing neuronal cell death related
to mitochondrial Ca2+ overload16,17, where a subtle or partial
depolarization of mitochondria to avoid Aβ-related mito-
chondrial Ca2+ overload in culture cells was protective for
neuronal death. Furthermore, our in vitro data show that
soluble Aβ increases [Ca2+]mit, leading to activation of mPTP,
ΔΨm decrease and activation of caspases. Previous studies have
already linked Aβ, mPTP and cell death in AD in neurons54–56
and astrocytes57,58, but here we show that activation of mPTP is
downstream mitochondrial Ca2+ overload, as preventing mPTP
activation did not forestall mitochondrial Aβo-driven Ca2+
overload, but avoided mitochondrial depolarization and caspase
activation. Moreover, we have previously shown that there is a
rapid cell death once Aβ-triggered oxidative stress invades
neuronal cell bodies in vivo in the same mouse model40. Oxi-
dative stress started in neurites, but in a small fraction of
neurons tracked towards the cell bodies leading to rapid
initiation of apoptosis. Mitochondrial Ca2+ overload has an
important role in the oxidative stress-induced neuronal cell
death59. Our findings of occasional rapid neuronal loss
after mitochondrial Ca2+ overload support our previous find-
ings and, more importantly, suggest a close link between
high [Ca2+]mit, oxidative stress and neuronal apoptosis via
mitochondria in AD.
Of note, the neurotoxic effect of Aβo on mitochondria were not
restricted to Ca2+ elevation, but also involved changes in mito-
chondrial size and shape. Indeed, the APP/PS1 Tg mouse model
exhibits structural abnormalities in mitochondria, including
mitochondria swelling and fragmentation11, and impaired bal-
ance of mitochondrial fission and fusion proteins has been shown
in brains from AD patients60. Aβ-induced mitochondrial frag-
mentation has been reported to precede neuronal cell death61.
Further experiments are necessary to monitor the morphological
changes and altered dynamics of mitochondria induced by Aβo
in vivo.
Here we show that blocking the MCU complex in vivo prevents
the Aβ-related mitochondrial Ca2+ overload, pointing to a critical
role of MCU in the mitochondrial Ca2+ overload mediated by
Aβo. Multiple lines of evidence support MCU as a candidate
therapeutic target against AD: MCU overexpression in mito-
chondria increased [Ca2+]mit following excitotoxicity through
activation of NMDA receptors in vitro, leading to mitochondrial
membrane depolarization and cell death62. Besides, inhibition of
MCU by Ru360, or silencing by siRNA or miRNA, conferred
resistance to oxidative stress to the cells in vitro63. Also, reducing
mitochondrial Ca2+ uptake by a null mutation in the gene
encoding MCU, improved mitochondrial function and sup-
pressed neurodegeneration in a C. elegans model of AD; and
preventing mitochondrial Ca2+ uptake by pre-treatment with
Ru360 decreased ROS levels in familial AD fibroblasts64. Our
in vitro work shows that preventing activation of the mPTP
downstream mitochondrial Ca2+ overload could also serve as a
therapeutic approach against AD, to protect mitochondria from
depolarization (loss of ΔΨm) and subsequent activation of
apoptosis.
In summary, our findings demonstrate that Aβ accumulation
provokes mitochondrial Ca2+ overload in vivo via the MCU
complex, leading to neuronal death. We have unveiled a patho-
physiological link between Ca2+ dyshomeostasis and mitochondrial
dysfunction hypotheses of AD pathogenesis and propose the inhi-
bition of the MCU complex and blocking of the mPTP activation as
novel therapeutic approaches against AD.
Methods
Animals. Mouse experiments were performed with the approval of the Massa-
chusetts General Hospital Animal Care and under the guidelines of Institutional
Animal Care and Use Committees (IACUC, protocol #2004N000047) for the use of
experimental animals. Mice used included: (1) APPswe/PSEN1ΔE9 double Tg mice
(The Jackson laboratory, B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, MMRRC
Cat# 034832-JAX, RRID:MMRRC_034832-JAX) (APP/PS1, 2- to 3-mo-old and 8-
to 10-mo-old) of either sex, expressing both human APP gene carrying the Swedish
mutation and exon 9 deletion mutation in the PS1 gene along with age-matched
Wt-littermate controls; and (2) C57BL/6J males (4- to 5-mo-old, Charles River) for
the application of the conditioned media and Ru360. For preparation of the con-
ditioned media, Tg2576 males (Taconic Farms, B6;SJL-Tg(APPSWE)2576Kha,
IMSR Cat# TAC:1349, RRID:IMSR_TAC:1349), which heterozygously overexpress
human APPswe under the PrP promoter, were mated with Wt females for pre-
paration of primary cortical neurons. Mice were socially housed at 3–4 animals per
cage with ad libitum access to food and water on a 12/12 h light/dark cycle with
controlled conditions of temperature and humidity.
hsyn.2mtYC3.6 and CBA.YC3.6 AAV construction and production. The
expression of the Ca2+ indicator Yellow Cameleon 3.6 (YC3.6)19 was targeted to
mitochondria by using the mitochondrial targeting sequence cytochrome oxidase
subunit 8 A (COX8A) at the N terminus, duplicated in tandem to enhance the
specificity of its localization65. 2mtYC3.6 was inserted on the 5′-end and in frame
with the cDNA of YC3.6, which we had previously cloned in an AAV.CBA.2m-
tYC3.6-WPRE (woodchuck hepatitis virus post-transcriptional regulatory element)
backbone. We then cut out the 2mtYC3.6 cDNA (NheI/XhoI-fill-in) and subcloned
it into an AAV-hSyn backbone obtained from the UPENN vector core, obtaining
the final AAV.hSyn.2mtYC3.6-WPRE plasmid. The integrity of the inverted
terminal repeats (ITRs) was verified by sequencing and SmaI digestion. Flanked by
the ITRs, the expression cassette included the following components, (1) a 1.7-kb
sequence containing human synapsin 1 gene promoter, (2) 2mt (mitochondrial
targeting sequence), (3) YC3.6, (4) WPRE and (5) Simian virus 40 (SV40). See
construct in Fig. 1a. High titers of AAV serotype 8 were produced using triple
transfection in HEK293 cells by the Schepens Eye Research Institute Gene Transfer
Vector Core. The virus titer was 5.7 × 1012 viral genomes copies per mL.
To measure cytosolic Ca2+ concentration we used the construct pAAV.CBA.
YC3.6-WPRE5. The plasmid contained AAV terminal repeats (ITRs) and the
expression cassette, which included the following components: the hybrid
cytomegalovirus (CMV) immediate-early enhancer/chicken β-actin promoter/
exon1/intron; yellow cameleon 3.6 cDNA and woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE). High titers of AAV serotype 8 were
produced using triple transfection in HEK293 cells by the Schepens Eye Research
Institute Gene Transfer Vector Core. The virus titer was 1.1 × 1012 viral genomes
copies per mL.
Cell culture and transfection. Primary neuronal cultures were obtained from
cerebral cortex of CD1 mouse embryos (Charles Rives Laboratories) at gestation
day 14–16. Neurons were dissociated using Papain dissociation system (Wor-
thington Biochemical Corporation, Lakewood, NJ, USA) and were maintained for
10–14 days in vitro (DIV) in Neurobasal medium containing 2% B27 supplement
(Gibco), 1% penicillin/streptomycin (Gibco) and 1% glutamax (Gibco) in a
humidified 37 °C incubator with 5% CO2 without further media exchange5.
N2a cells were maintained in OptiMEM (Gibco) supplemented with 5% Fetal
Bovine Serum (FBS) (Atlanta Biologicals) and 1% penicillin and 1% streptomycin
(Gibco) in a humidified 37 °C incubator with 5% CO2.
Cells were transiently transfected at 70–80% confluence with 4 µg of
hSyn.2mtYC3.6 and mRuby-Mito-7 (gift from Michael Davidson Addgene,
#55874) plasmids using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions.
In situ calibration of hSyn.2mtYC3.6 in N2a cells. N2a cells were plated in 35
mm glass-bottom dishes (MatTek Corporation) and transfected with lipofectamine
2000 (Life Technologies) and 4 μg of the hSyn.2mtYC3.6 construct. 24 h after
transfection, cells were permeabilized for 1 min with 100 µM digitonin in intra-
cellular medium (130 mM KCl, 5 mM NaCl, 1 mM MgCl2, 2 mM KH2PO4, 20 mM
HEPES, 0.5 mM EGTA, 5 mM succinate, 1 mM ATP, pH 7), followed by three
washes with intracellular medium devoid of digitonin. After permeabilization, cells
were exposed to solutions containing known Ca2+ concentration (ranging from
0 µM to 1 mM) and 10 µM FCCP, to depolarize mitochondria and equilibrate the
[Ca2+] in the medium and in the organelle66. Calibration solutions with free Ca2+
concentration <20 µM were prepared by mixing intracellular media with the che-
lators EGTA or HEDTA and 1M CaCl2 according to MaxChelator Ca-EGTA
Calculator (https://somapp.ucdmc.ucdavis.edu/pharmacology/bers/maxchelator/
CaEGTA-NIST.htm) and to Park and Palmer67. Calibration solutions with free
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Ca2+ concentration >20 µM were made by adding various volumes of 1M CaCl2 to
the intracellular media solution. 2 photon excitation was used at 860 nm, and
emitted light was collected in three channels in the range of 380–480, 500–540 and
560–650 nm. Images were acquired on an Olympus FluoView FV1000MPE mul-
tiphoton laser-scanning system mounted on an Olympus Bx61WI microscope, and
photomultiplier settings were selected and maintained for the intravital imaging.
YFP/CFP fluorescence ratios were plotted against free Ca2+ concentration and
fitted with a sigmoid equation. The apparent Kd (Kd′) and Hill coefficient (n)
were determined as described previously20. Custom-written ImageJ software
(https://imagej.nih.gov/ij/) was used for analysis and calculation of YFP/CFP ratios.
Note that ratios increased with increasing [Ca2+]. Ratios were then converted to







Preparation of Wt and TgCM and Aβ-immunodepleted media. Primary neu-
ronal cultures were prepared as described above5. Neurons were plated on 35-mm
culture PDL-coated dishes. Tissue from each embryo was collected for genotyping
by PCR. Neurons were maintained in Neurobasal media (Gibco) containing 2%
B27 supplement (Gibco), 1% penicillin/streptomycin (Gibco) and 1% glutamax
(Gibco) for 14 DIV. Conditioned media from either Tg cultures (TgCM) or their
Wt littermates (WtCM) was collected, and the concentration of Aβ40 was measured
by mouse/human ELISA kit (Wako #294-64701 Human/Rat Aβ1–40).
Immunodepletion of human Aβ from the TgCM was performed overnight by
using the mouse antibody 6E10 (Purified anti-β-Amyloid, 1–16 antibody
BioLegend Cat# 803004, RRID: AB_2715854) and protein G sepharose beads
(Sigma-Aldrich). Briefly, protein G beads were washed with cold Neurobasal
medium in order to avoid non-specific binding. Then, 1 mL of TgCM was
incubated with 40 µL of the pre-washed protein G beads and 6 µg of 6E10 antibody
overnight at 4 °C under rotation. Finally, the supernatant was collected and the Aβ
concentration was quantified by mouse/human ELISA kit (Wako #294-64701
Human/Rat Aβ1-40) according to the manufacturer’s instructions.
Mitochondrial and cytosolic calcium in vitro imaging. Primary cortical neurons
obtained from CD1 embryos were cultured for 12–15 days in vitro (DIV) and
infected with AAV.hSyn.2mtYC3.6 to target mitochondria. Experiments were
performed using sister cultures obtained on the same day to control for any
culture-to-culture variation. Three days after infection, cells were incubated with
fresh conditioned media and subjected to multiphoton microscopy. 5–6 fields of
view were imaged randomly. For some experiments cortical neurons infected
with the mitochondrial reporter hSyn.2mtYC3.6 were loaded with the calcium
indicator calbryte 590 (0.5 µM) for 30 min at room temperature to measure Ca2+
changes in the cytosol and mitochondria simultaneously. Images were acquired
in an Olympus FluoView FV1000MPE multiphoton laser-scanning system
mounted on an Olympus Bx61WI microscope. Two photon excitation was used
at 800 nm (for calbryte) and 860 nm (for 2mtYC3.6), and emitted light was
collected in the range of 380–480, 500–540 and 560–650 nm. Either images were
acquired in basal conditions and after treatment with conditioned media, or
time-lapse recordings were acquired following stimulation with KCl (50 mM) or
TgCM. Background fluorescence corresponding to regions devoid of cells was
subtracted. Images were analyzed using custom-written MATLAB scripts (see
Image Analysis section).
Mitochondrial permeability transition pore (mPTP) activity. mPTP opening
was directly assessed by the calcein/cobalt method68. Briefly, primary cortical
neurons cultured for 12–15 DIV were co-loaded with calcein-AM 1 µM, CoCl2
1 mM and Hoechst 33342 1 µM for 15 min at room temperature and imaged
with confocal microscopy. The effect of TgCM was evaluated longitudinally.
Images were acquired in the green channel (488 nm) every 10 min. Cells were
maintained at 37 °C and 5% CO2 during the recording. Fluorescence traces from
mitochondria in individual cells were normalized relative to their value before
addition of any solutions (t= 0 min). Background fluorescence corresponding to
regions devoid of cells was subtracted. In some experiments, cells were pre-
incubated with cyclosporine A 1 µM for 15 min before and co-applied during the
recording.
Mitochondrial membrane potential (ΔΨm) imaging. The effects of TgCM on
ΔΨm were evaluated by confocal microscopy in cells loaded with the ΔΨm sen-
sitive probe TMRE. Primary cortical neurons cultured for 12–15 DIV were loaded
with TMRE (10 nM) and Hoechst 33342 1 µM for 15 min at room temperature and
imaged with confocal microscopy. The effect of TgCM was evaluated long-
itudinally. Cells were maintained at 37 °C and 5% CO2 during the recording.
Excitation of the neurons was performed at 361 nm for Hoechst and 549 nm for
TMRE, and images were taken every 10 min. Fluorescence traces from individual
cells were normalized relative to their value before addition of any solutions (t=
0 min). Background fluorescence corresponding to regions devoid of cells was
subtracted. In some experiments, cells were pre-incubated with cyclosporine A
1 µM for 15 min before and co-applied during the recording.
Caspase activation imaging. Caspase activation was detected with CellEvent
Caspase 3/7 Green Detection Reagent in primary cortical neurons at 12–15 DIV.
Neurons were labeled with CellEvent Caspase 3/7 5 µM and Hoechst 33342 1 µM
for 15 min at room temperature. Then media was replaced by the conditioned
media and green fluorescence was detected under confocal microscopy. Excitation
of the neurons was performed at 361 nm for Hoechst and 488 nm for CellEvent,
and images were recorded every 10 min. Cells were maintained at 37 °C and 5%
CO2 during the recording. Fluorescence traces from individual cells were nor-
malized relative to their value before addition of any solutions (t= 0 min). Back-
ground fluorescence corresponding to regions devoid of cells was subtracted. In
some experiments, cells were pre-incubated with cyclosporine A 1 µM for 15 min
before and co-applied during the recording.
Stereotactic intracortical injection of AAVs. Four- to five-mo-old C57BL/6 J Wt
mice were injected intracortically with AAV.hSyn.2mtYC3.6 (serotype 2/8) or
pAAV.CBA.YC3.6-WPRE (serotype 2/8). Stereotactic intracortical injections were
performed as previously described7. Briefly, mice were anesthetized with 1.5%
(vol/vol) isoflurane and positioned on a stereotactic frame (Kopf Instruments).
Body temperature was maintained throughout the surgery with a heating pad. 3 µL
of viral suspension were injected in the somatosensory cortex using a 33-gauge
sharp needle (Hamilton Medical) attached to a 10 µL Hamilton microsyringe
(Hamilton Medical), at a rate of 0.15 µL/min. Stereotactic coordinates of the
injection sites were calculated from bregma (anteroposterior −1 mm, mediolateral
±1 mm and dorsoventral −0.8 mm).
Eight- to nine-mo-old APP/PS1 Tg mice were injected intracortically with
AAV.hSyn.2mtYC3.6 at the moment of the cranial window implantation with 3 µL
of viral suspension in the somatosensory cortex (left hemisphere) at 0.15 µL/min,
followed by cranial window implantation. In some cases, 1 µl of Hoechst 33342
1uM was co-injected with AAV.hSyn.2mtYC3.6 to label nuclei in the area of
injection. Mice were given buprenorphine (0.1 mg/kg) for 3 days following surgery.
Cranial window implantation. In the acute conditioned media experiments, a
6 mm cranial window was implanted in the C57BL/6J Wt mice three to four weeks
after AAV.hSyn.2mtYC3.6 or pAAV.CBA.YC3.6-WPRE injection. Mice were
anesthetized with 1.5% (vol/vol) isoflurane and placed in a stereotactic apparatus.
A piece of skull over somatosensory cortex was removed and replaced with an
8 mm diameter glass coverslip7. Dura matter was removed before window instal-
lation and the window was sealed containing PBS. Texas Red dextran (70,000 MW;
12.5 mg/mL in PBS; Molecular Probes) was retro-orbitally injected to provide a
fluorescent angiogram. An imaging session was first performed to determine the
basal resting [Ca2+]mit. Then, the window was removed and sealed again with
WtCM, TgCM, Aβ-immunodepleted TgCM, Ru360 (Calbiochem, Merck Milli-
pore) or Ru360 + TgCM (final volume applied was 40 μL). In the last case, Ru360
was pre-incubated for 15 min previous application of TgCM. After 1 h, each mouse
was reimaged at the same fields of view to determine the relative changes in [Ca2+]
(ΔR/R0).
For the APP/PS1 Tg mice, cranial windows were implanted to the animals
following the intracortical virus injection. Mice were anesthetized with 1.5%
(vol/vol) isoflurane and placed in a stereotactic apparatus. A piece of skull over left
somatosensory cortex was removed, replaced with a 5 mm diameter glass coverslip
and fixed with Krazy Glue and dental cement7. Mice were given buprenorphine
(0.1 mg/kg) for 3 days following surgery. Expression of the virus was allowed for
3–4 weeks before imaging. Methoxy-XO4 (4 mg/kg) was intraperitoneally injected
1 day before the imaging session to label amyloid plaques21.
In vivo multiphoton microscopy imaging. Mice were anesthetized with isoflurane
(5% inhalation, mixed with pure O2) for induction, and a reduced concentration of
isoflurane (~1.5%) was used during the imaging. The animal’s body temperature
was maintained at ~37.5 °C during the imaging session with a heating pad; oph-
thalmic ointment was applied to protect the eyes. Mice were visually monitored
throughout the duration of the imaging session (which lasted on average 2 h).
Images of AAV.hSyn.2mtYC3.6 or pAAV.CBA.YC3.6-WPRE expressing neurons,
amyloid pathology and Texas Dextran Red angiograms were obtained by using an
Olympus FlouView FV1000MPE multiphoton laser-scanning system mounted on
an Olympus Bx61WI microscope and an Olympus 25× dipping objective (NA=
1.05). A Deep-See Mai Tai Ti:Sapphire mode-locked laser (Mai Tai; Spectra-phy-
sics) generated multiphoton excitation at 860 nm, and three photomultiplier tubes
(PMTs) (Hamamatsu) collected the emitted light in the range of 380–480, 500–540
and 560–650 nm69. Images were taken at 5× zoom. Five to fifteen cortical volumes
(Z-series, 127 µm × 127 µm, 200–300 µm depth) were acquired per mouse, at a
resolution of 512 × 512 pixels. CFP and YFP PMTs settings remained unchanged
throughout the different imaging sessions. Laser power was adjusted as needed and
kept below 50mW to avoid phototoxicity70.
At the end of the last imaging session, APP/PS1 Tg mice were euthanized under
CO2, perfused with phosphate buffered saline (PBS, Gibco) and brains were
removed. The hemisphere injected with AAV.hSyn.2mtYC3.6 was fixed with 4%
paraformaldehyde and 15% glycerol for 24 h, frozen in mounting media on ice cold
isopropanol and sliced into 20 µm sections on a cryostat (Leica). The other
hemisphere was flash frozen with liquid nitrogen and stored at −80 °C until use.
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Image analysis. Multiphoton microscopy imaging data, acquired in vivo, were
analyzed by using a custom-written MATLAB (MathWorks) script. To perform
automatic segmentation of mitochondria, an adaptive thresholding procedure was
applied to generate binary images and individual mitochondria were selected using
a constraint on object size. Amyloid plaques were manually extracted from the z-
stacks. To obtain Yellow Cameleon ratio values, the data were preprocessed by
subtracting the background from the CFP and YFP channels (mean of the bottom
5% of intensity values in each slice of the z-stack) and applying a mean filter with
radius 2 to each channel. The ratio for each mitochondrion was calculated by
dividing the sum of the intensity values corresponding to the mitochondrion in the
YFP channel by the sum of intensity values in the CFP channel. The YFP/CFP
ratios were mapped to mitochondrial Ca2+ concentrations using the in situ cali-
bration curves (see In situ calibration of 2mtYC3.6 in N2a cells section). Calcium
pseudocolored images were created using MATLAB by first assigning the [Ca2+]
values to a RGB (red, green, blue) colormap with the color range determined by the
empirical values for Rmin and Rmax. The RGB image was then converted to an HSV
(hue, saturation, value) image with the ‘value’ field set to the mean of the YFP and
CFP intensity images. Distance to plaque was measured based on the centroid of
the mitochondrion to the edge of the nearest plaque. To assess changes in mito-
chondrial morphology, a unique slice per z-stack was selected, matching the region
across the three different time points (basal, 1 h, 8 h). Slices were selected within
30-60 μm depth. ROIs were drawn around individual mitochondria with the free
hand selection tool in ImageJ based on the pseudocolor images. About 100–125
random individual mitochondria were taken. Matlab was used to measure the
parameters of interest (area, perimeter and circularity) for each ROI. Area and
perimeter were determined as the total number of pixels within the ROI and the
number of pixels outlining the ROI, respectively, and then converted to physical
units of μm2 and μm. Circularity was calculated using the formula, Perimeter2/
4πArea. Images presented in the figures are either a single slice from the z-stack or
2D maximum intensity projections of the z-stack.
Mitochondrial-enriched fraction and Western blotting. Frozen hemibrains
devoid of cerebellum from APP/PS1 mice were lysed in Tris-buffered saline (TBS)
with 2% sodium dodecyl sulfate (SDS) and protease inhibitor (Roche Diagnostics) at
10% (w/vol) in a 5 mL glass dounce homogenizer. Tissue was dounce homogenized
with 25 up/down strokes by hand and incubated for 30min at 37 °C. The homo-
genate was then centrifuged at 100,000 × g for 30 min at 20 °C. The supernatant was
collected, aliquoted and stored at −80 °C until use. Mitochondrial-enriched fraction
was obtained using a mitochondrial isolation kit (mitochondrial isolation kit for
mammalian tissue samples, Abcam) according to the manufacturer’s instructions.
A bicinchonic acid assay (BCA, Thermo Scientific Pierce) was used to determine
protein sample concentration. Supernatants were subjected to SDS-PAGE on
NuPAGE Bis-tris gels (Life Technologies). Briefly, 20 µg of total protein per well
were loaded on 4–12% Bis-Tris SDS-PAGE gels and run in MES buffer (Invitrogen).
Proteins were then transferred to PVDF membranes (Millipore), which were
incubated overnight with the primary antibodies: rabbit anti-MCU (1:1000, Sigma-
Aldrich Cat# HPA016480, RRID:AB_2071893), rabbit anti-MiCU1 (1:1000, Sigma-
Aldrich Cat# HPA037480, RRID:AB_10696934), rabbit anti-EFHA1 (MiCU2)
(1:500, Abcam Cat# ab101465, RRID:AB_10711219), rabbit anti-SLC24A6 (NCLX)
(1:250, Sigma-Aldrich Cat# SAB2102181, RRID:AB_10606696), mouse anti-
VDAC1/porin (1:1000, Abcam Cat# ab14734, RRID:AB_443084), mouse anti-β-
tubulin I (1: 10,000, Sigma-Aldrich Cat# T7816, RRID:AB_261770). The next day,
blots were incubated with infrared secondary goat anti-mouse IgG IRDye680 or
goat anti-rabbit IgG IRDye800 (1: 5,000, LICOR) for 1 h at room temperature, and
imaged on an Odyssey Infrared Imaging System (LICOR). Blots were converted to
gray scale and densitometry analysis was performed using Image Studio Lite Ver5.2.
Immunohistochemistry. 20 µm coronal sections were subjected to antigen retrie-
val, permeabilized with 0.5% triton X-100 and incubated with antibodies against
GFP (chicken anti-GFP IgY, 1:500, Aves Labs Cat# GFP-1020, RRID: AB_2307313),
HSP60 (rabbit anti-HSP60, 1:500, Abcam Cat# ab46798, RRID:AB_881444), NeuN
(mouse anti-NeuN, 1:500 Millipore Cat# MAB377, RRID:AB_2298772) and GS
(rabbit anti-Glutamine Synthetase, 1:500, Abcam Cat# ab73593, RRID:
AB_2247588) overnight at 4 °C. Appropriate secondary antibodies (Alexa fluor 488-
conjugated goat anti-chicken IgG antibody, 1:500, Molecular Probes Cat# A-11039,
RRID:AB_142924, Cy3-conjugated goat anti-rabbit IgG antibody, 1:1000, Abcam
Cat# ab6939, RRID:AB_955021, Cy3-conjugated goat anti-mouse IgG antibody,
1:1000, Abcam Cat# ab97035, RRID:AB_10680176, and Cy5-conjugated goat anti-
rabbit IgG antibody, 1:1000, Jackson ImmunoResearch Labs Cat# 111-175-144,
RRID:AB_2338013) were applied and incubated for 1 h at room temperature. Slices
were mounted with DAPI Vectashield (Vector Laboratories) and subjected to
fluorescence imaging.
Analysis of publicly available human brain datasets. 25 microarray and RNA-
Sequencing (RNA-seq) datasets from the Mount Sinai Brain Bank (MSBB)43 and
the Religious Orders Study and Memory and Aging Project (ROSMAP)44 cohorts,
spanning 19 brain regions, were analyzed as described in Bihlmeyer et al.71 Four of
these brain regions had both microarray and RNA-Seq data. The samples were
grouped by the Braak score, which assesses the distribution of tau neurofibrillary
tangles in the subject’s brain72. The expression of 8 mitochondrial genes involved
in mitochondrial Ca2+ homeostasis (MCU, MCUB, MCUR1, MICU1, MICU2,
MICU3, SMDT1 and SLC8B1) was compared in AD Braak stages (V–VI) versus
control subjects (Braak 0–I–II) and by CERAD analysis (frequent versus absent
neuritic amyloid plaques). Data were adjusted for neuronal loss with the pan-
neuronal marker MAP2. Multiple comparisons corrections were performed using
the Benjamini–Hochberg method73. For the purpose of selection for visual display,
a FDR threshold of 0.25 was used. All results for the differential expression analysis
are listed in Supplementary Tables S1 and S2.
Statistics. Statistical analyses were conducted in SAS and GraphPad 5.0. Data are
reported as mean ± SEM. To assess differences between groups (Wt vs. APP/PS1;
Basal vs. WtCM/TgCM/Aβ-depleted TgCM/TgCM+Ru360/Ru360), global and
pair-wise, for all measurements of interest (YFP/CFP Ratio, Ca2+ overload and
ΔR/R0), a linear mixed effects model was fitted with treatment group as fixed effect
and mouse as random effect. The least square mean and standard error estimates
and the p-values resulting from these models are presented in the figure legends.
Similarly, estimates for basal, 1 h post CM application and 8 h post CM application
mean and SE measurements were generated from a linear mixed effects model with
a fixed effect of an intercept only and a random effect of mouse. Kruskal–Wallis
test was used for the analysis of the relationship between percent of Ca2+ overload
and distance to the edge of the plaque. p < 0.05 was considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its Supplementary Information files or from the corresponding author
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